Repare Therapeutics Inc. is a biotechnology company focused on cancer treatment innovation through precision medicine. The company's primary function is to develop therapeutics that target genetic weaknesses in cancer cells, particularly by employing a therapeutic approach known as synthetic lethality. This approach allows for the precise identification of genes that can be targeted to selectively kill cancer cells while sparing healthy ones. Repare Therapeutics operates largely within the biopharmaceutical sector, with research and development investments aimed at discovering and advancing novel cancer therapies. The significance of Repare Therapeutics in the market stems from its specialized approach towards oncology, contributing to personalized medicine efforts and promising potential breakthroughs in cancer treatment. Founded with cutting-edge genomic technologies, the company collaborates with scientific experts globally, positioning itself as a noteworthy player in the landscape of cancer genetics research and drug development.
www.reparerx.com